Skip to main content
padlock icon - secure page this page is secure

Recent Progress in the Development of Small Molecule c-Met Inhibitors

Buy Article:

$68.00 + tax (Refund Policy)

C-Met, also referred to as Hepatocyte Growth Factor Receptor (HGFR), is a heterodimeric receptor tyrosine kinase. It has been determined that c-Met gene mutations, overexpression, and amplification also occur in a variety of human tumor types, and these events are closely related to the aberrant activation of the HGF/c-Met signaling pathway. Meanwhile, high c-Met expression is closely associated with poor prognosis in cancer patients. The c-Met kinase has emerged as an attractive target for developing antitumor agents. In this review, we cover the recent advances on the small molecule c-Met inhibitors discovered from 2018 until now, with a main focus on the rational design, synthesis and structureactivity relationship analysis.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Anticancer agents; Drug development; Small molecule inhibitors; Structure-activity relationship analysis; Tyrosine kinase; c-Met

Document Type: Review Article

Publication date: June 1, 2019

This article was made available online on July 17, 2019 as a Fast Track article with title: "Recent Progress in the Development of Small Molecule c-Met Inhibitors".

More about this publication?
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more